Zerion Pharma and the Spanish pharmaceutical group Insud Pharma will develop and commercialize drug products applying ZERION’s Dispersome technology.
Zerion will develop Dispersome formulations of marketed drug products while Insud will be responsible for the finished product dosage form, the clinical development as well as global marketing and sales of the final products.
A worldwide exclusive license
The companies started working together in 2021 and the partnership has now resulted in the first Dispersome drug product being ready for upscaling, GMP manufacture and human clinical trials. Zerion has granted Insud a worldwide exclusive license to this first Dispersome drug formulation. Under the terms of the license agreement, Insud will pay Zerion license fees, as well as milestone fees and royalties on product sales. Insud will cover all clinical and other development costs.
“This partnership also provides early validation of an important element in our business strategy, that is to improve solubility and bioavailability of already marketed drug products.”
“I am truly excited by our partnership with Insud Pharma that I consider a very innovative and dynamic pharma company with global commercial reach. We appreciate Insud’s readiness to explore innovative approaches to improve existing drug products,” says Ole Wiborg, CEO of Zerion. “This partnership also provides early validation of an important element in our business strategy, that is to improve solubility and bioavailability of already marketed drug products. Zerion has a number of internal development programs in this field but we did not expect to complete commercial partnerships this soon.”
The two companies are working together on a second product candidate and expect more products to be included in the collaboration.